design, and scalable hardware to expand throughput while maintaining product consistency. Capabilities include the design of bioreactor components, process monitoring, and quality controls aligned to plasma-derived medicines. The goal is to reduce supply shortages for essential immunoglobulin therapies and create a path to broader access for donor-based biologics.